Children with hematological malignancy (C91.0
Conditions
Interventions
Group 1: Children with hematological malignancy/children undergoing hematopoietic stem cell transplantation
data captured include age, underlying malignancy, temperature
diagostic ruslts (e.g., galactomannan, imaging studies)
administration of antifungal compounds
Sponsors
Pädiatrische Hämatologie und OnkologieKlinik für Kinder- und JugendmedizinJohann Wolfgang Goethe Universität
Eligibility
Sex/Gender
All
Age
0 Days to 18 Years
Inclusion criteria
Inclusion criteria: • Children and adolescents 0 to <18 years who are diagnosed with acute lymphoblastic leukemia, acute myeloid leukemia, relapse of acute leukemia or receive an allogeneic hematopoietic stem cell transplantation in the University Children´s Hospitals of Frankfurt, Münster or in St. Anna Kinderspital, Vienna, respectively • Diagnosis of the malignancy/ transplantation between April 1, 2014 and March 31, 2016 • Written informed consent is mandatory for enrollment in the study.
Exclusion criteria
Exclusion criteria: • Patients without written informed will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| to describe the epidemiology of invasive fungal infections in three major pediatric cancer centers in Germany/Austria | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) to characterize risk factors and periods of risk for invasive fungal infections in different pediatric patient populations (e.g., children suffering from ALL, AML etc) 2) outcome of invasive fungal infections in pediatric cancer patients | — |
Countries
Austria, Germany
Contacts
Public ContactThomas Lehrnbecher
Pädiatrische Hämatologie und OnkologieKlinik für Kinder- und JugendmedizinJohann Wolfgang Goethe Universität
Outcome results
None listed